Answers are grounded in this paper and cite their sources.
Background/Objectives: Routine laboratory markers may characterise FIB-4 risk profiles in adults with diabetes. This study examined associations between FIB-4 and an exploratory composite of gamma-glutamyl transferase (GGT), neutrophil-to-lymphocyte ratio (NLR) and red cell distribution width (RDW), termed GNR-3, and assessed whether the composite provided measurable discrimination beyond GGT alone. Methods: A cross-sectional secondary analysis included 60 adults with documented diabetes and prospectively collected baseline data. FIB-4 and GNR-3 were recalculated from the supplied anonymised records. Analyses included rank correlations, covariate-adjusted associations, false-discovery-rate adjustment and paired receiver operating characteristic comparisons. Confidence intervals were estimated using 20,000 participant-level bootstrap samples. The binary discrimination endpoint was high FIB-4 (>2.67), not a confirmed diagnosis of liver fibrosis. Results: Low, intermediate and high FIB-4 classifications occurred in 9, 36 and 15 participants, respectively. GNR-3 correlated with FIB-4 (ρ = 0.364, 95% confidence interval [CI] 0.093–0.596) and retained an association after adjustment for age and sex (partial ρ = 0.351, q = 0.0274). Apparent areas under the receiver operating characteristic curve for high FIB-4 were 0.811 for GNR-3 and 0.753 for GGT. Their paired difference was 0.058 (95% CI −0.048 to 0.166, DeLong p = 0.275), providing no evidence that the composite discriminated high FIB-4 better than GGT alone. Age-adapted classification reclassified nine participants without changing the high category. Conclusions: GNR-3 was associated with FIB-4 in this small exploratory cohort, but its apparent discrimination of high FIB-4 did not demonstrate an advantage over GGT alone. These findings concern FIB-4 risk classification rather than diagnosis of liver fibrosis and do not support clinical use of the composite. Independent evaluation using clinically characterised liver outcomes would be required before considering further application.
No takes yet. Share an insight, caveat, or question.
Pădureanu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: